Navigation Links
The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone
Date:3/23/2010

d would expand its commercial infrastructure to support European marketing efforts. Given the significant unmet medical need for medications to treat patients with IPF, the approval of pirfenidone in Europe would represent a second and important value-creation opportunity to that represented by the U.S. market.

U.S. Regulatory Status

The New Drug Application (NDA) for pirfenidone was submitted by InterMune to the United States Food and Drug Administration (FDA) in early November 2009. On January 4, 2010, InterMune announced that the FDA granted Priority Review designation for its New Drug Application (NDA) for pirfenidone for the treatment of IPF. Priority Review designation may be granted by the FDA to an NDA for drugs that have the potential to offer major advances in treatment, or provide a treatment where no adequate therapy exists. Based on the Prescription Drug User Fee Act, the FDA has set an action date for the NDA of May 4, 2010. On March 9, the FDA's Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted 9-3 to recommend the approval of pirfenidone for the treatment of U.S. patients with IPF to reduce decline in lung function.

About Esbriet® (pirfenidone)


'/>"/>
SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Promega Maxwell 16 IVD System CE Marked to the European Union IVD Directive Delivers Combined Solution for Infectious Disease
2. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
3. International Collaboration: FDA and European Medicines Agency Agree to Accept a Single Orphan Drug Designation Annual Report
4. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
5. Your e-Marketing Journey in 2010: An e-Book for Corporate Communicators Working in European Headquarters
6. Lower detection of prostate cancer with PSA screening in US than in a European randomized trial
7. European Cancer Organization supports a revision of the EU Clinical Trials Directive
8. Abbott Receives European Regulatory Approval for New Ovarian Cancer Diagnostic Test
9. Cardiome Announces Investigational Candidate, Vernakalant, Meets Primary Endpoint in European Comparator Study
10. The European Society of Cardiology Textbook of Cardiovascular Imaging puts patient at center
11. Reportlinker Adds European Markets for Interventional Cardiology 2009 (15 Countries)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... May 04, 2015 San Diego ... ceremony at their brand new, 13,700 square foot facility ... new building will not only provide fertility treatment and ... also offer community and educational events to a number ... is located next door to their current Carmel Valley/Del ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Unlike some camps, the ... imparting knowledge. The goal is to educate first and train ... This ensures that the young runners are building the knowledge ... A few of the topics covered include Effort Based Training, Running ... I used to be? This is not a camp where ...
(Date:5/4/2015)... Pa. (PRWEB) May 04, 2015 Sylvia Hawthorn-Deppen ... the hopes that it would remind others in similar situations ... A Recovery from Chronic Pain and Discovery of New Energy” ... with a new audience via a renewed press campaign. , ... with debilitating pain ,” Hawthorn-Deppen says. “As an adolescent ...
(Date:5/4/2015)... “ Food Cost Calculator ” was featured ... a look at the latest and coolest applications on the ... of AppWatch and technology expert, conducted the app review and ... manage and efficiently calculate food costs. , The restaurant industry ... the industry has an estimated 1.8 trillion dollar impact on ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 “St. Louis ... the “Gateway to the West,” so it is the ... Veterans Program”, says Dr. Ben Litalien, Chief Development Officer ... Association’s VetFran program and will provide veterans with a ... Zerorez® is proud to have a number of Military ...
Breaking Medicine News(10 mins):Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:Author launches new press campaign for 2012 book ‘Wheel’ 2Health News:An Application to Manage a Successful Restaurant Was Featured on NewsWatch Television 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 2Health News:Zerorez® Creates “Gateway” for Veterans--Announces VetFran Participation. Plans Expansion into the St. Louis Region. 3
... Fewer Kidneys ,Kidney Donations by the Poor Are on ... with low incomes are more likely to develop kidney failure ... than people of other socioeconomic classes. Because fewer individuals in ... Hospital, University of British Columbia, in Vancouver, Canada) and colleagues ...
... HealthDay Reporter , FRIDAY, Nov. 19 (HealthDay News) -- Computer ... they,ll look after a "nose job," and the majority value ... The "morphing" software, used by plastic surgeons since the 1990s, ... study said. "Having an image of an individual in ...
... (HealthDay News) -- Male teens with disruptive behavior disorders ... in a traffic crash, either as a driver or ... risk is similar to that of epilepsy patients, said ... Canada, and his colleagues. Disruptive behavior disorders include ...
... By Ellin Holohan HealthDay Reporter , ... people ride motorcycles without wearing helmets in the United ... crashes are creating huge medical costs, two new companion ... all traumatic brain injuries sustained in motorcycle crashes involving ...
... 16, 2010) A clinical trial that aims to speed ... of breast cancer now has a designated study site ... University of Colorado Hospital. This study, called I-SPY ... Response with Imaging and Molecular Analysis 2) will evaluate ...
... medicine is a new lead in the search for compounds ... findings, reported by Vanderbilt University Medical Center researchers in the ... fresh approach for developing therapeutics that target the pathway. More ... second deadliest type of cancer in the developed world ...
Cached Medicine News:Health News:Efforts needed to address disparities in kidney transplantation 2Health News:Efforts needed to address disparities in kidney transplantation 3Health News:Efforts needed to address disparities in kidney transplantation 4Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 2Health News:Computer Imaging Adds to 'Nose Job' Satisfaction: Study 3Health News:Behavior Disorders Boost Crash Risk for Teen Boys: Study 2Health News:Young Motorcycle Riders Suffering More Brain Injuries 2Health News:Young Motorcycle Riders Suffering More Brain Injuries 3Health News:I-SPY 2 study speeds up treatment for breast cancer 2Health News:I-SPY 2 study speeds up treatment for breast cancer 3Health News:New path for colon cancer drug discovery 2
(Date:5/4/2015)...  CytRx Corporation (Nasdaq: CYTR ), a ... today announced an interim analysis from its two ... with either gemcitabine or ifosfamide. Both studies combine ... doses of aldoxorubicin. The combinations appear to be ... level of aldoxorubicin (170 mg/m2), impressive tumor responses ...
(Date:5/4/2015)... May 4, 2015  Geneia, a company of ... solutions to improve healthcare efficiencies, today announced a ... Center (BNRC) use Geneia,s advanced analytics solution ... the quality and lower the cost of patient ... outcomes, claims and utilization data from multiple sources ...
(Date:5/4/2015)... INDIANAPOLIS , May 4, 2015 ... released two new reports that provide a comprehensive ... reports highlight how Lilly is evolving its approach ... and capabilities in partnership with others to have ... 2014 Corporate Responsibility Update offers a thorough ...
Breaking Medicine Technology:CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 2CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 3CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 4CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 5CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 6CytRx Reports Aldoxorubicin Demonstrates Both Tumor Shrinkage and Improved Quality of Life in Chemotherapy Resistant Cancers 7Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 2Geneia Launches First-of-its-Kind Partnership to Use Advanced Analytics to Improve the Quality and Cost of Care for Skilled Nursing and Rehabilitation Patients 3Lilly Releases Corporate Responsibility, Global Health Reports 2Lilly Releases Corporate Responsibility, Global Health Reports 3Lilly Releases Corporate Responsibility, Global Health Reports 4
... , , BERLIN ... NKTR ) presented favorable data today on lead oncology program, ... investigational compound in ovarian cancer. These data were presented at ... Oncology (ESMO) 2009 Joint Multidisciplinary Congress in Berlin, Germany. , ...
... , , , ... a Phase II trial of regorafenib (BAY 73-4506), a potent oral multi-kinase ... partial response rate and 50 percent stabilization rate in patients with metastatic ... at the joint 15th Congress of the European CanCer Organisation and 34th ...
Cached Medicine Technology:NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 2NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 3NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 4NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress 5Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 2Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 3Bayer's Novel Anti-Cancer Compound Regorafenib (BAY 73-4506) Showed Stabilization or Regression in 81 Percent of Kidney Cancer Patients 4
Rounded tip spatula with 20 gauge shaft. Black finish for reduced glare....
Triangular 0.5 mm angled tip with 4 mm flat surface. Round knurled handle with dull finish. Tip angle: 110o. Most popular size or model....
10 mm angled tip with indentation on side and gently curved blade. Round knurled handle with polished finish. Indentation: left side....
0.5 mm x 15 mm angled round blade with smoothly pointed tip and gently curved blade. Round knurled handle with polished finish....
Medicine Products: